Kovina Therapeutics is a pre-clinical stage biotechnology company that is dedicated to developing groundbreaking antiviral therapeutics to combat Human Papillomavirus (HPV) related infections and associated cancers. With millions of people worldwide affected by HPV, and an estimated 630,000 HPV-related malignancies diagnosed annually, Kovina is committed to providing novel treatment options for patients infected with HPV. Unlike the HPV vaccine, which only prevents new infections, Kovina's unique antiviral approach focuses on curing HPV by targeting and inactivating a key protein expressed in early, pre-malignant, and cancerous pathologies.

Their proprietary drug-like compounds have the potential to halt the progression of HPV infections before they develop into cancer, as well as treating HPV-related cancers after detection. Led by a team of experienced leaders and experts, Kovina Therapeutics is at the forefront of pioneering therapies that offer hope for non-surgical treatment options for cancers and premalignant infections caused by HPV. Through their research and development efforts, they aim to provide patients with innovative solutions that are currently unavailable in the market.

Reach out to Kovina today to learn more about their groundbreaking work in the field of HPV therapeutics